Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Multicenter Open-Label Phase III Study of Emicizumab in Hemophilia A
2016-001094-33Phase 3Suspended
- Sponsor
- Roche
- Start
- Jul 2016
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of emicizumab in hemophilia A, sponsored by Roche. Started Jul 2016; status: suspended.
02
Drugs
emicizumab
03
Conditions
hemophilia A
Beyond the preview
Go deeper on 2016-001094-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-001094-33.